Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly

World Journal of Surgical Oncology

David L. Morris²  Winston Liauw³  Jing Zhao⁴  Saleh E. Alzahrani⁴  Nayef A. Alzahrani⁵  Yeqian Huang¹ 

[1] St George Clinical School, University of New South Wales, St George Hospital, New South Wales, Australia;Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, University of New South Wales, Level 3 Pitney Building, Gray Street, Kogarah, Sydney 2217, NSW, Australia;Department of Medical Oncology, St George Hospital, Sydney, New South Wales, Australia;Department of Surgery, University of New South Wales, St George Hospital, New South Wales, Australia;College of Medicine, Imam Muhammad ibn Saud Islamic University, Riyadh, Saudi Arabia

关键词: Elderly;    Peritoneal carcinomatosis;    Peritonectomy;    Cytoreductive surgery;   

Others  :  1223958
DOI  :  10.1186/s12957-015-0682-7

 received in 2015-05-08, accepted in 2015-08-17,  发布年份 2015

【 摘 要 】

Background

Peritoneal carcinomatosis is life-threatening without cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC). Only a few studies in the literature addressed the relationship between age and outcomes of peritonectomy. This study was designed to review the clinical outcomes in elderly patients who underwent CRS and PIC.

Methods

This is a retrospective study of prospectively collected data of 611 consecutive patients with peritoneal carcinomatosis who underwent CRS and PIC by the same surgical team at St George Hospital in Sydney, Australia, between January 1996 and December 2013. Patients were divided into two groups; group 1 (<65 years old, n = 487) and group 2 (≥ 65 years old, n = 124). Subgroup analysis was performed in patients who were ≥75 years old (n = 20). A significant difference was defined as p < 0.05.

Results

There was no significant statistical difference in terms of mean total hospital stay, intensive care unit stay, high dependency unit stay and complication rates. Postoperative mortality was 2 and 3 % in groups 1 and 2, respectively. Overall survival did not reach a statistical significance between the two groups. In subgroup analysis, patients showed similar morbidity results to patients who were <65 years old.

Conclusions

CRS and PIC can be safely done in the elderly. Age alone should not be the single exclusion criterion but rather taken into consideration along with other factors to determine the suitability of elderly patients.

【 授权许可】

   
2015 Huang et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G et al.. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999; 6(8):790-6.
• [2]Spiliotis JD. Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepato-Gastroenterology. 2009; 57(102–103):1173-7.
• [3]Teo M, Foo K, Koo W, Wong L, Soo K. Lessons learned from initial experience with peritonectomy and intra-peritoneal chemotherapy infusion. World J Surg. 2006; 30(12):2132-5.
• [4]Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999; 6(8):727-31.
• [5]Chua TC, Liauw W, Zhao J, Morris DL. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013; 18(3):439-46.
• [6]Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg. 2009; 249(6):900-7.
• [7]Spiliotis J, Halkia E, Boumis V, Vassiliadou D, Pagoulatou A, Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Intern J Surg Oncol. 2014; 2014:987475.
• [8]Mueller H, Hahn M, Simsa J. Cytoreductive surgery in the elderly patients--is it feasible? Hepato-Gastroenterology. 2007; 55(88):2005-11.
• [9]Macri A, Saladino E, Trimarchi G, Bartolo V, Rossitto M, Cannao A et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. In Vivo. 2011; 25(4):687-90.
• [10]Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal carcinomatosis: principles of management: US: Springer; 1996: 359–74.
• [11]Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221(1):29-42.
• [12]Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205.
• [13]Cooper C, Hagan P. The ageing Australian population and future health costs: 1996–2051. Occasional Papers: New Series Number 7. 2008.
• [14]Statistics AB. Life expectancy trends- Australia. Australian Bureau of Statistics, Canberra; 2011. [cited 2014 Oct 20], Available from: http://www. abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Main+Features10Mar+2011
• [15]Marcantonio E, Goldman L, Rohde LE, Orav J, Mangione CM, Lee TH. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med. 2001; 134(8):637-43.
• [16]Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, Stewart JH et al.. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013; 20(11):3497-503.
• [17]Chua TC, Martin S, Saxena A, Liauw W, Yan TD, Zhao J et al.. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg. 2010; 251(2):323-9.